Q2FY23 Preview: Cipla: Revenue seen at Rs60,038 million, PAT at Rs8,413 million

3 Nov 2022 , 10:44 AM

Result date: 4^th November, 2022
Recommendation: Buy
Target price: Rs1,150
(Source: IIFL Research)

Cipla is likely to post 9% growth in revenue over the year-ago quarter. This growth would be led by strong show in the domestic formulations business across all key segments. The company’s US sales too could remain strong, particularly with the launch of gRevlimid.

The company’s EBITDA could grow 13.63%, while Profit After Tax (PAT) could grow 18.27% over the year-ago quarter.

Important management insights to watch out for:

• New product launches
• Outlook on US markets
• Margin trends

Rs. Million	September 2022 estimates	QoQ change	YoY change
Revenue	60,038	12.10%	9.00%
EBITDA	13,663	21.57%	13.63%
Profit After Tax	8,413	22.53%	18.27%

Source: Brokerage Reports